Maravai LifeSciences (NASDAQ:MRVI) Stock Price Down 4.7% – Should You Sell?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s stock price was down 4.7% during mid-day trading on Tuesday . The stock traded as low as $3.27 and last traded at $3.3350. Approximately 308,114 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 2,054,138 shares. The stock had previously closed at $3.50.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company lifted their price target on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research report on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Tuesday, October 14th. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Maravai LifeSciences presently has a consensus rating of “Hold” and a consensus price target of $5.25.

Maravai LifeSciences Stock Performance

The stock has a market cap of $849.98 million, a price-to-earnings ratio of -3.95 and a beta of 0.32. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.29 and a quick ratio of 4.56. The stock’s 50-day moving average is $3.41 and its 200-day moving average is $2.86.

Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%.The business had revenue of $41.63 million for the quarter, compared to analysts’ expectations of $49.02 million. Analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.

Insider Activity at Maravai LifeSciences

In related news, CEO Bernd Brust bought 216,212 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was purchased at an average cost of $3.25 per share, for a total transaction of $702,689.00. Following the completion of the acquisition, the chief executive officer owned 466,771 shares in the company, valued at $1,517,005.75. This trade represents a 86.29% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gregory T. Lucier purchased 48,528 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The shares were bought at an average cost of $3.67 per share, with a total value of $178,097.76. Following the transaction, the director directly owned 155,123 shares of the company’s stock, valued at $569,301.41. The trade was a 45.53% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 566,771 shares of company stock worth $1,880,244 over the last three months. Corporate insiders own 2.11% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Nuveen LLC bought a new stake in Maravai LifeSciences in the first quarter valued at $666,000. Philosophy Capital Management LLC bought a new position in Maravai LifeSciences in the 1st quarter worth approximately $5,731,000. Jacobs Levy Equity Management Inc. increased its position in Maravai LifeSciences by 437.0% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 493,582 shares of the company’s stock valued at $1,091,000 after acquiring an additional 401,673 shares during the period. Strs Ohio bought a new stake in Maravai LifeSciences during the 1st quarter valued at $429,000. Finally, Parkman Healthcare Partners LLC boosted its position in Maravai LifeSciences by 88.6% during the 1st quarter. Parkman Healthcare Partners LLC now owns 660,000 shares of the company’s stock worth $1,459,000 after acquiring an additional 310,000 shares during the period. 50.25% of the stock is owned by hedge funds and other institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.